The ExteNET trial, a multicenter, randomized Phase III study, evaluated the efficacy of neratinib in patients with early‐stage HER2‐positive breast cancer, showing improved 2‐year invasive disease‐free survival (DFS) compared to placebo after trastuzumab therapy in an adjuvant setting (93.9% vs. 91.6%, p = 0.0091) [10]. The gene discussed is ERBB2; the disease is breast carcinoma.